IBIO Stock Overview
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
iBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.72 |
| 52 Week High | US$27.80 |
| 52 Week Low | US$1.02 |
| Beta | -3.52 |
| 1 Month Change | 60.75% |
| 3 Month Change | 62.56% |
| 1 Year Change | -93.38% |
| 3 Year Change | -99.74% |
| 5 Year Change | -99.58% |
| Change since IPO | -99.96% |
Recent News & Updates
Shareholder Returns
| IBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.9% | -4.7% | -3.7% |
| 1Y | -93.4% | -2.7% | 20.2% |
Return vs Industry: IBIO underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: IBIO underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| IBIO volatility | |
|---|---|
| IBIO Average Weekly Movement | 56.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IBIO's share price has been volatile over the past 3 months.
Volatility Over Time: IBIO's weekly volatility has increased from 31% to 56% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 26 | Martin Brenner | www.ibioinc.com |
iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever.
iBio, Inc. Fundamentals Summary
| IBIO fundamental statistics | |
|---|---|
| Market cap | US$15.24m |
| Earnings (TTM) | -US$20.77m |
| Revenue (TTM) | US$50.00k |
296.2x
P/S Ratio-0.7x
P/E RatioIs IBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBIO income statement (TTM) | |
|---|---|
| Revenue | US$50.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$50.00k |
| Other Expenses | US$20.82m |
| Earnings | -US$20.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.41 |
| Gross Margin | 100.00% |
| Net Profit Margin | -41,546.00% |
| Debt/Equity Ratio | 142.8% |
How did IBIO perform over the long term?
See historical performance and comparison